Is Yield10 Bioscience, Inc. overvalued or undervalued?

As of 8 March 2018, Yield10 Bioscience, Inc. has moved from a grade of risky to does not qualify, indicating a significant deterioration in its valuation outlook. The company is considered overvalued given its negative financial ratios, including a P/E ratio of -0.0008 and an EV to EBITDA of -0.08, both of which reflect a lack of profitability and operational efficiency. The current price of $0.01 is a stark contrast to its 52-week high of $2.33, highlighting the substantial decline in market perception.
In comparison to peers, Yield10 Bioscience's valuation metrics are notably poor. For instance, CVR Partners LP is rated very attractive with a P/E of 12.50, while Oil-Dri Corp. of America shows a strong P/E of 22.31. This stark contrast underscores the challenges Yield10 faces in attracting investor interest. Additionally, the company's year-to-date return of -95.19% compared to the S&P 500's 2.44% reinforces the notion that it is significantly overvalued in the current market environment.